Tofacitinib fails to prevent T cell transfer colitis in mice but ameliorates disease activity
Abstract Tofactinib is a JAK inhibitor approved for ulcerative colitis in humans. Despite of its’ proven effectiveness in humans, mechanistic data are scarce on the effectiveness of Tofactinib in experimental colitis in mice. We induced experimental colitis by transfer of CD4+CD25− isolated T cells...
Main Authors: | Sudheendra Hebbar Subramanyam, Judit Turyne Hriczko, Angeliki Pappas, Angela Schippers, Nobert Wagner, Kim Ohl, Klaus Tenbrock |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2023-03-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-023-30616-w |
Similar Items
-
Pediatric IBD patients show medication and disease activity dependent changes in NK cell and CD4 memory T cell populations
by: Angeliki Pappa, et al.
Published: (2023-06-01) -
CD11c-Specific Deletion Reveals CREB as a Critical Regulator of DC Function during the Germinal Center Response
by: Kim Ohl, et al.
Published: (2018-01-01) -
NRF2/Itaconate Axis Regulates Metabolism and Inflammatory Properties of T Cells in Children with JIA
by: Anandhi Rajendiran, et al.
Published: (2022-12-01) -
The role and prospect of tofacitinib in patients with ulcerative colitis
by: Jun Lee
Published: (2023-01-01) -
Amelioration of unstable vitiligo and normalization of thryroglobulin antibodies with oral tofacitinib
by: Angela Yen Moore, MD, et al.
Published: (2022-05-01)